Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors
Open Access
- 27 March 2009
- journal article
- Published by Springer Nature in Psychopharmacology
- Vol. 205 (1), 21-33
- https://doi.org/10.1007/s00213-009-1513-8
Abstract
We evaluated the effects of haloperidol and its metabolites on capsaicin-induced mechanical hypersensitivity (allodynia) and on nociceptive pain induced by punctate mechanical stimuli in mice. Subcutaneous administration of haloperidol or its metabolites I or II (reduced haloperidol) dose-dependently reversed capsaicin-induced (1 μg, intraplantar) mechanical hypersensitivity of the hind paw (stimulated with a nonpainful, 0.5-g force, punctate stimulus). The order of potency of these drugs to induce antiallodynic effects was the order of their affinity for brain sigma-1 (σ1) receptor ([3H](+)-pentazocine-labeled). Antiallodynic activity of haloperidol and its metabolites was dose-dependently prevented by the selective σ1 receptor agonist PRE-084, but not by naloxone. These results suggest the involvement of σ1 receptors, but discard any role of the endogenous opioid system, on the antiallodynic effects. Dopamine receptor antagonism also appears unlikely to be involved in these effects, since the D2/D3 receptor antagonist (−)-sulpiride, which had no affinity for σ1 receptors, showed no antiallodynic effect. None of these drugs modified hind-paw withdrawal after a painful (4 g force) punctate mechanical stimulus in noncapsaicin-sensitized animals. As expected, the control drug gabapentin showed antiallodynic but not antinociceptive activity, whereas clonidine exhibited both activities and rofecoxib, used as negative control, showed neither. These results show that haloperidol and its metabolites I and II produce antiallodynic but not antinociceptive effects against punctate mechanical stimuli and suggest that their antiallodynic effect may be due to blockade of σ1 receptors but not to dopamine receptor antagonism.Keywords
This publication has 60 references indexed in Scilit:
- Activation of the spinal sigma‐1 receptor enhances NMDA‐induced pain via PKC‐ and PKA‐dependent phosphorylation of the NR1 subunit in miceBritish Journal of Pharmacology, 2008
- A new sigma ligand, (±)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effectLife Sciences, 2008
- S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side EffectsJournal of Pharmacology and Experimental Therapeutics, 2007
- The sigma‐1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampusThe Journal of Physiology, 2006
- Intrathecal treatment with σ1 receptor antagonists reduces formalin‐induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in miceBritish Journal of Pharmacology, 2006
- Haloperidol in the Acute Treatment of Migraine: A Randomized, Double‐Blind, Placebo‐Controlled StudyHeadache: The Journal of Head and Face Pain, 2006
- In vivo evaluation of (+)-MR200 as a new selective sigma ligand modulating MOP, DOP and KOP supraspinal analgesiaLife Sciences, 2005
- Intrathecal α2 adrenoceptor agonist clonidine inhibits mechanical transmission in mouse spinal cord via activation of muscarinic M1 receptorsNeuroscience Letters, 2002
- Capsaicin and nociception: from basic mechanisms to novel drugsThe Lancet, 2000
- Modulation of nmda and dopaminergic neurotransmissions by sigma ligands: Possible implications for the treatment of psychiatric disordersLife Sciences, 1996